Wellcome Trust Sanger Institute:製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9402)
◆英語タイトル:Wellcome Trust Sanger Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9402
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:53
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥28,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥57,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥85,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Wellcome Trust Sanger Institute (Sanger Institute) a subsidiary of Genome Research Ltd is a genomic discovery and research centre that carries out research and development in the areas of cellular and human genetics and infection genomics. It also provides postgraduate training on research and the clinical applications of genomics in human and infectious disease. Sanger Institute works in collaboration with academic, industrial, biotech and pharmaceutical industries for national and international projects. It is funded by Wellcome Trust, UK Research Councils, Charities, the EU and NIH. The institute has facilities for protein mass spectrometry, fluorescence activated cell sorting and cytogenetics and single cell genomics. Sanger Institute is headquartered in Hinxton, the UK.

Wellcome Trust Sanger Institute – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Wellcome Trust Sanger Institute, Medical Devices Deals, 2012 to YTD 2018 10
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Sigma-Aldrich Enters into Agreement with Sanger Institute 12
AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 13
Blueprint Medicines Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center 14
Licensing Agreements 15
Oxford Gene Enters into Licensing Agreement with Wellcome Trust Sanger Institute 15
Equity Offering 16
Microbiotica Spin Off from Wellcome Trust Sanger Institute 16
Wellcome Trust Sanger Institute – Key Competitors 17
Wellcome Trust Sanger Institute – Key Employees 18
Wellcome Trust Sanger Institute – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Government and Public Interest 20
Sep 12, 2018: Study links common arthritis drug azathioprine to skin cancer 20
Sep 03, 2018: Regulator protein key to malaria parasite’s lifecycle 21
Aug 09, 2018: Human Cell Atlas gets a boost with first funding from Wellcome 22
Jul 16, 2018: New study finds CRISPR/Cas9 gene editing causes greater DNA damage 24
Jun 18, 2018: Genomics offers new treatment options for infants with range of soft tissue tumours 25
Jun 12, 2018: Genetic discovery will help clinicians identify aggressive versus benign bone tumours 26
May 03, 2018: Deadliest human malaria parasite reveals the genomic chinks in its armour 27
May 02, 2018: Worm experiments offer new insight into mutational causes of cancer 28
Apr 11, 2018: Single cell technology and organoids reveal every bowel tumour and bowel cancer cell have unique genetic fingerprints 30
Mar 20, 2018: Switch discovered to convert blood vessels to blood stem cells during embryonic development 31
Mar 19, 2018: New osteoarthritis genes discovered 32
Feb 20, 2018: Typhoid outbreak: genetic cause of extensive drug resistance found 34
Dec 08, 2017: £3.9m project to support elimination of the world’s leading infectious cause of blindness 35
Nov 27, 2017: Unforseen new drug target discovered for acute myeloid leukaemia 37
Oct 23, 2017: Five new malaria targets that could lead to an effective vaccine 38
Oct 11, 2017: New type of stem cell line produced offers expanded potential for research and treatments 39
Sep 13, 2017: Immunotherapy treatment option for selected breast cancer patients, genetic study suggests 41
Sep 07, 2017: The Brain Tumour Charity grants WINDOW Consortium £1.5 million for new research into combination therapies to treat brain cancer 42
Jul 13, 2017: Largest study of malaria gene function reveals many potential drug targets 43
Mar 23, 2017: New stem cell method produces millions of human brain and muscle cells in days 44
Mar 03, 2017: Latest genomic technology uncovers secrets of immune system’s response to malaria 45
Feb 10, 2017: Malaria vaccine target’s invasion partner uncovered 46
Product News 47
Oct 19, 2017: Thermo Fisher Scientific and Wellcome Trust Sanger Institute Announce the Axiom Africa Array for Medical and Population Genomics 47
May 08, 2018: Machine learning flags emerging pathogens 48
Other Significant Developments 49
Oct 26, 2018: Cancer Gene Census to help improve personalised medicine 49
Jun 06, 2018: Wellcome Sanger Institute Sequences Reference Genomes of 3,000 Dangerous Bacteria 50
Nov 09, 2017: Australia joins world-first Human Cell Atlas effort 51
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Key Facts 2
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Wellcome Trust Sanger Institute, Deals By Therapy Area, 2012 to YTD 2018 9
Wellcome Trust Sanger Institute, Medical Devices Deals, 2012 to YTD 2018 10
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Sigma-Aldrich Enters into Agreement with Sanger Institute 12
AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 13
Blueprint Medicines Enters Into Co-Development Agreement With Wellcome Trust Sanger Institute And Massachusetts General Hospital Cancer Center 14
Oxford Gene Enters into Licensing Agreement with Wellcome Trust Sanger Institute 15
Microbiotica Spin Off from Wellcome Trust Sanger Institute 16
Wellcome Trust Sanger Institute, Key Competitors 17
Wellcome Trust Sanger Institute, Key Employees 18
Wellcome Trust Sanger Institute, Other Locations 19

List of Figures
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Wellcome Trust Sanger Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Wellcome Trust Sanger Institute, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Wellcome Trust Sanger Institute:製薬・医療:M&Aディール及び事業提携情報(Wellcome Trust Sanger Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆